Health Technology Research Center, National Institute of Advanced Industrial Science and Technology, Osaka, Japan.
J Gastroenterol Hepatol. 2010 Jan;25(1):107-15. doi: 10.1111/j.1440-1746.2009.05928.x. Epub 2009 Sep 25.
The possible involvement of oxidative stress in hepatitis C virus (HCV)-induced liver damage and hepatocarcinogenesis has been reported. We have recently developed a novel method to measure total hydroxyoctadecadienoic acid (tHODE) and have proposed its usefulness as a biomarker for lipid peroxidation. The present study was undertaken to evaluate oxidative stress in HCV-infected liver diseases by several potential oxidative stress markers including tHODE and further to validate the biomarkers for evaluating the efficacy of iron reduction therapy.
Total hydroxyoctadecadienoic acid, total 8-iso-prostagrandin F(2alpha) (t8-iso-PGF(2alpha)), selenoprotein P and other antioxidant compounds were measured in the plasma and erythrocytes obtained from 42 healthy controls and 78 HCV patients. Plasma levels of biomarkers and antioxidants were also assessed during the iron reduction therapy for 16 weeks in 12 HCV patients.
The concentrations of tHODE in the plasma and erythrocytes and t8-iso-PGF(2alpha) in the plasma of chronic HCV-infected patients were significantly higher than those of healthy controls. Plasma levels of vitamin E and vitamin C of HCV-infected patients were lower than those of the controls. Furthermore, the plasma tHODE significantly correlated with serum aminotransferases and type IV collagen-7S domain in chronic HCV-infected patients. During the iron reduction therapy, the plasma levels of tHODE but not t8-iso-PGF(2alpha) decreased and inversely its stereo-isomer ratio (ZE/EE) increased in parallel with the decreases of serum alanine aminotransferase, ferritin and alpha-fetoprotein.
The levels of tHODE in chronic HCV-infected patients can be a useful biomarker for the evaluation of oxidative stress in chronic hepatitis C.
据报道，氧化应激可能参与丙型肝炎病毒（HCV）引起的肝损伤和肝癌发生。我们最近开发了一种测量总羟基十八碳二烯酸（tHODE）的新方法，并提出其作为脂质过氧化生物标志物的有用性。本研究旨在通过几种潜在的氧化应激标志物（包括 tHODE）评估 HCV 感染性肝病中的氧化应激，并进一步验证用于评估铁还原治疗疗效的生物标志物。
从 42 名健康对照者和 78 例 HCV 患者中获得的血浆和红细胞中测量总羟基十八碳二烯酸、总 8-异前列腺素 F2α（t8-iso-PGF2α）、硒蛋白 P 和其他抗氧化化合物。还在 12 例 HCV 患者的 16 周铁还原治疗期间评估了血浆生物标志物和抗氧化剂的水平。
慢性 HCV 感染患者的血浆和红细胞中 tHODE 浓度以及血浆中 t8-iso-PGF2α 浓度明显高于健康对照组。HCV 感染患者的血浆维生素 E 和维生素 C 水平低于对照组。此外，血浆 tHODE 与慢性 HCV 感染患者的血清转氨酶和 IV 型胶原 7S 结构域显著相关。在铁还原治疗期间，血浆 tHODE 水平（而非 t8-iso-PGF2α 水平）下降，其立体异构体比值（ZE/EE）增加，与血清丙氨酸氨基转移酶、铁蛋白和甲胎蛋白的下降平行。
慢性 HCV 感染患者的 tHODE 水平可作为评估慢性丙型肝炎氧化应激的有用生物标志物。
